HRP20161785T1 - Farmaceutski pripravak sporog oslobađanja pripremljen od mikročestica - Google Patents
Farmaceutski pripravak sporog oslobađanja pripremljen od mikročestica Download PDFInfo
- Publication number
- HRP20161785T1 HRP20161785T1 HRP20161785TT HRP20161785T HRP20161785T1 HR P20161785 T1 HRP20161785 T1 HR P20161785T1 HR P20161785T T HRP20161785T T HR P20161785TT HR P20161785 T HRP20161785 T HR P20161785T HR P20161785 T1 HRP20161785 T1 HR P20161785T1
- Authority
- HR
- Croatia
- Prior art keywords
- microparticles
- group
- groups
- preparation according
- pharmaceutical preparation
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title claims 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims 4
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims 4
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims 3
- 235000014655 lactic acid Nutrition 0.000 claims 3
- 239000004310 lactic acid Substances 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims 2
- 229960004824 triptorelin Drugs 0.000 claims 2
- ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical group C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229960000294 triptorelin pamoate Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (10)
1. Farmaceutski pripravak pripremljen od mikročestica za sporo oslobađanje LHRH agonista triptorelina, naznačeno time što taj pripravak sadrži prvu skupinu mikročestica i drugu skupinu mikročestica, gdje
a) mikročestice te prve skupine su napravljene od kopolimera PLGA tipa u kojem je inkorporiran taj LHRH agonist u obliku peptidne soli netopljive u vodi; taj kopolimer obuhvaća najmanje 85% (molarno) mliječne kiseline i ima inherentnu viskoznost između 0.5 i 0.9 dl/g, kako je mjereno u kloroformu na 25°C i pri koncentraciji polimera od 0.5 g/dL;
b) mikročestice te druge skupine su napravljene od kopolimera PLGA tipa u kojem je inkorporiran taj LHRH agonist u obliku peptidne soli netopljive u vodi i koji obuhvaća količinu mliječne kiseline između 70% i 80% (molarno);
mikročestice te prve i druge skupine dalje imaju raspodjelu čestica definiranu kako slijedi:
- D (v,0.1) je između 10 i 30 mikrometara,
- D (v,0.5) je između 30 i 70 mikrometara,
- D (v,0.9) je između 50 i 110 mikrometara,
taj farmaceutski pripravak oslobađa LHRH agonist triptorelin najmanje kroz period od 6 mjeseci nakon injekcije tog pripravka.
2. Farmaceutski pripravak prema zahtjevu 1, gdje taj kopolimer u prvoj skupini obuhvaća najmanje 85% (molarno) mliječne kiseline i ima inherentnu viskoznost između 0.55 i 0.75 dl/g.
3. Farmaceutski pripravak prema zahtjevu 1 ili 2, gdje su te mikročestice prve skupine, ili druge skupine, ili obje skupine, mikrosfere.
4. Farmaceutski pripravak prema zahtjevu 1 ili 2, gdje su te mikročestice prve skupine, ili druge skupine, ili obje skupine, mikrogranule.
5. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 4, gdje je inherentna viskoznost kopolimera u drugoj skupini između 0.5 i 0.9, poželjno između 0.60 i 0.70 dl/g.
6. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5, gdje su obje skupine mikročestica u dozirnom omjeru, izraženom kao sadržaj peptida od 50:50.
7. Farmaceutski pripravak prema zahtjevu 1 ili 2, gdje se barem jedna od tih skupina mikročestica dobiva miješanjem PLGA a peptidnom soli netopljivom u vodi, u postupku bez otapala.
8. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 7, gdje ta peptidna sol netopljiva u vodi jest triptorelin pamoat.
9. Uporaba pripravka prema bilo kojem od zahtjeva 1 do 8 u pripremi lijeka za liječenje raka prostate, naznačena time što se pripravak daje jednom svakih 6 mjeseci.
10. Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 8 za uporabu u liječenju raka prostate, gdje se taj pripravak daje jednom svakih 6 mjeseci.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07109767 | 2007-06-06 | ||
IB2007054372 | 2007-10-27 | ||
PCT/IB2008/052241 WO2008149320A2 (en) | 2007-06-06 | 2008-06-06 | Slow release pharmaceutical composition made of microparticles |
EP08763237.8A EP2164467B1 (en) | 2007-06-06 | 2008-06-06 | Slow release pharmaceutical composition made of microparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161785T1 true HRP20161785T1 (hr) | 2017-03-10 |
Family
ID=40032512
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161785TT HRP20161785T1 (hr) | 2007-06-06 | 2016-12-27 | Farmaceutski pripravak sporog oslobađanja pripremljen od mikročestica |
HRP20181854TT HRP20181854T1 (hr) | 2007-06-06 | 2018-11-07 | Farmaceutski pripravak sporog oslobađanja pripremljen od mikročestica |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20181854TT HRP20181854T1 (hr) | 2007-06-06 | 2018-11-07 | Farmaceutski pripravak sporog oslobađanja pripremljen od mikročestica |
Country Status (32)
Country | Link |
---|---|
US (3) | US10166181B2 (hr) |
EP (3) | EP2164467B1 (hr) |
JP (1) | JP5419169B2 (hr) |
KR (1) | KR101631475B1 (hr) |
CN (1) | CN101677959B (hr) |
AP (1) | AP3000A (hr) |
AU (1) | AU2008259411B2 (hr) |
BR (1) | BRPI0812250B8 (hr) |
CA (1) | CA2688478C (hr) |
CO (1) | CO6251234A2 (hr) |
CY (2) | CY1118434T1 (hr) |
DK (2) | DK2164467T3 (hr) |
EA (1) | EA019284B1 (hr) |
ES (2) | ES2611020T3 (hr) |
HK (1) | HK1141737A1 (hr) |
HR (2) | HRP20161785T1 (hr) |
HU (2) | HUE040391T2 (hr) |
IL (1) | IL202501A (hr) |
LT (2) | LT2164467T (hr) |
MA (1) | MA31422B1 (hr) |
ME (1) | ME00959B (hr) |
MX (1) | MX2009012856A (hr) |
MY (1) | MY150450A (hr) |
NZ (1) | NZ582423A (hr) |
PL (2) | PL2500014T3 (hr) |
PT (2) | PT2164467T (hr) |
RS (2) | RS58248B1 (hr) |
SI (2) | SI2164467T1 (hr) |
TN (1) | TN2009000476A1 (hr) |
UA (1) | UA99830C2 (hr) |
WO (1) | WO2008149320A2 (hr) |
ZA (1) | ZA200907940B (hr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2164467T (lt) | 2007-06-06 | 2017-01-25 | Debiopharm Research & Manufacturing Sa | Lėto atpalaidavimo mikrodalelių farmacinė kompozicija |
PT105270B (pt) | 2010-08-26 | 2012-05-31 | Domino Ind Ceramicas S A | Camada de sílica com libertação lenta de fragrância, telha cerâmica e respectivo processo de produção |
CN105267153B (zh) * | 2015-11-27 | 2018-05-11 | 上海苏豪逸明制药有限公司 | 一种曲普瑞林缓释微粒及其制备方法 |
CN105797134B (zh) * | 2016-03-29 | 2019-06-14 | 浙江圣兆药物科技股份有限公司 | 一种难溶亮丙瑞林缓释制剂 |
WO2018083633A1 (en) | 2016-11-02 | 2018-05-11 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
KR102402639B1 (ko) | 2017-11-24 | 2022-05-26 | 삼성전자주식회사 | 전자 장치 및 그의 통신 방법 |
CN111000798B (zh) * | 2019-12-26 | 2021-11-23 | 四川恒博生物科技有限公司 | 一种采用原位凝胶技术的犬用非手术去势注射液 |
IT202000017191A1 (it) | 2020-07-15 | 2022-01-15 | Xbrane Biopharma Ab | Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE61935T1 (de) | 1985-02-07 | 1991-04-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von mikrokapseln. |
US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
US5225205A (en) * | 1989-07-28 | 1993-07-06 | Debiopharm S.A. | Pharmaceutical composition in the form of microparticles |
CH679207A5 (hr) * | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
FR2693905B1 (fr) * | 1992-07-27 | 1994-09-02 | Rhone Merieux | Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues. |
JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
DK0724431T3 (da) * | 1993-10-22 | 2003-01-06 | Genentech Inc | Fremgangsmåder og sammensætninger til mikroindkapsling af adjuvanser |
US5945128A (en) * | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
TW577759B (en) | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
JP2001522812A (ja) * | 1997-11-07 | 2001-11-20 | カイロン コーポレイション | Igf−1持続放出性処方物の作製方法 |
TWI284048B (en) * | 2000-01-27 | 2007-07-21 | Zentaris Ag | Compressed microparticles for dry injection |
US20040170665A1 (en) | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
MXPA04003433A (es) | 2001-10-10 | 2004-08-11 | Pf Medicament | Microesferas biodegradables de liberacion prolongada y metodo para preparar las mismas. |
CN1780634A (zh) * | 2003-04-30 | 2006-05-31 | 德比奥法姆股份有限公司 | 应用促性腺激素释放激素的组合物和方法 |
KR100466637B1 (ko) * | 2003-06-26 | 2005-01-13 | 주식회사 펩트론 | 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법 |
FR2865938B1 (fr) * | 2004-02-05 | 2006-06-02 | Sod Conseils Rech Applic | Formulation retard solide comprenant de l'acetate de triptoreline |
KR20130024987A (ko) | 2005-12-22 | 2013-03-08 | 노파르티스 아게 | 옥트레오티드 및 2종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제 |
LT2164467T (lt) | 2007-06-06 | 2017-01-25 | Debiopharm Research & Manufacturing Sa | Lėto atpalaidavimo mikrodalelių farmacinė kompozicija |
-
2008
- 2008-06-06 LT LTEP08763237.8T patent/LT2164467T/lt unknown
- 2008-06-06 ME MEP-2009-341A patent/ME00959B/me unknown
- 2008-06-06 US US12/601,649 patent/US10166181B2/en active Active
- 2008-06-06 ES ES08763237.8T patent/ES2611020T3/es active Active
- 2008-06-06 EP EP08763237.8A patent/EP2164467B1/en not_active Revoked
- 2008-06-06 HU HUE12172232A patent/HUE040391T2/hu unknown
- 2008-06-06 ES ES12172232.6T patent/ES2694401T3/es active Active
- 2008-06-06 DK DK08763237.8T patent/DK2164467T3/en active
- 2008-06-06 SI SI200831754A patent/SI2164467T1/sl unknown
- 2008-06-06 BR BRPI0812250A patent/BRPI0812250B8/pt active IP Right Grant
- 2008-06-06 RS RS20181349A patent/RS58248B1/sr unknown
- 2008-06-06 CA CA2688478A patent/CA2688478C/en active Active
- 2008-06-06 PL PL12172232T patent/PL2500014T3/pl unknown
- 2008-06-06 MY MYPI20094886 patent/MY150450A/en unknown
- 2008-06-06 JP JP2010510946A patent/JP5419169B2/ja active Active
- 2008-06-06 PL PL08763237T patent/PL2164467T3/pl unknown
- 2008-06-06 SI SI200832014T patent/SI2500014T1/sl unknown
- 2008-06-06 PT PT87632378T patent/PT2164467T/pt unknown
- 2008-06-06 EP EP18186642.7A patent/EP3431077A1/en active Pending
- 2008-06-06 AU AU2008259411A patent/AU2008259411B2/en active Active
- 2008-06-06 NZ NZ582423A patent/NZ582423A/en unknown
- 2008-06-06 AP AP2009005088A patent/AP3000A/xx active
- 2008-06-06 LT LTEP12172232.6T patent/LT2500014T/lt unknown
- 2008-06-06 KR KR1020107000176A patent/KR101631475B1/ko active IP Right Grant
- 2008-06-06 MX MX2009012856A patent/MX2009012856A/es active IP Right Grant
- 2008-06-06 EP EP12172232.6A patent/EP2500014B1/en active Active
- 2008-06-06 WO PCT/IB2008/052241 patent/WO2008149320A2/en active Application Filing
- 2008-06-06 UA UAA200913838A patent/UA99830C2/uk unknown
- 2008-06-06 HU HUE08763237A patent/HUE031550T2/en unknown
- 2008-06-06 RS RS20170032A patent/RS55591B1/sr unknown
- 2008-06-06 DK DK12172232.6T patent/DK2500014T3/en active
- 2008-06-06 PT PT12172232T patent/PT2500014T/pt unknown
- 2008-06-06 EA EA200971132A patent/EA019284B1/ru unknown
- 2008-06-06 CN CN200880018833.3A patent/CN101677959B/zh active Active
-
2009
- 2009-11-09 TN TNP2009000476A patent/TN2009000476A1/fr unknown
- 2009-11-11 ZA ZA200907940A patent/ZA200907940B/xx unknown
- 2009-12-01 MA MA32391A patent/MA31422B1/fr unknown
- 2009-12-02 CO CO09137855A patent/CO6251234A2/es not_active Application Discontinuation
- 2009-12-03 IL IL202501A patent/IL202501A/en active IP Right Grant
-
2010
- 2010-09-02 HK HK10108338.2A patent/HK1141737A1/xx unknown
-
2016
- 2016-12-27 HR HRP20161785TT patent/HRP20161785T1/hr unknown
-
2017
- 2017-01-17 CY CY20171100060T patent/CY1118434T1/el unknown
-
2018
- 2018-11-07 CY CY181101171T patent/CY1120891T1/el unknown
- 2018-11-07 HR HRP20181854TT patent/HRP20181854T1/hr unknown
- 2018-11-15 US US16/192,674 patent/US20190192423A1/en not_active Abandoned
-
2022
- 2022-09-15 US US17/932,621 patent/US20230082575A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161785T1 (hr) | Farmaceutski pripravak sporog oslobađanja pripremljen od mikročestica | |
CN101669900B (zh) | 更高效的利普安聚合物释放制剂 | |
HRP20180118T1 (hr) | Injekcijski tekući pripravak koji sadrži buprenorfin | |
CN100387228C (zh) | 可注射的美沙酮、部分类鸦片激动剂或类鸦片拮抗剂微粒组合物及其用途 | |
AU2006299657B2 (en) | Sustained release small molecule drug formulation | |
CN101522170B (zh) | 在延长的一段时间里释放活性成分的皮下植入剂 | |
US20040009226A1 (en) | Injectable system for controlled drug delivery | |
MX2009002757A (es) | Formulacion de farmaco resistente al abuso. | |
CN109862876A (zh) | 含有阴离子聚合物和阳离子聚合物或肽的复合粒子及其制造方法 | |
Koocheki et al. | Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride | |
CA2444145A1 (en) | Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illness and its complications | |
Kajihara et al. | Development of new drug delivery system for protein drugs using silicone (I) | |
Schilling et al. | Novel application of hot-melt extrusion for the preparation of monolithic matrices containing enteric-coated particles | |
CN101623255A (zh) | 一种青蒿琥酯纳米乳药物组合物及其制备方法 | |
Zaki Ahmad et al. | Feasibility of Assam Bora rice starch as a compression coat of 5-fluorouracil core tablet for colorectal cancer | |
CN103550150A (zh) | 改进的含二甲基硅油的注射剂 | |
CN101011341A (zh) | 一种含抗代谢类药物及拓扑酶抑制剂的缓释注射剂 | |
US10940118B2 (en) | Nanoparticles and methods of producing the same | |
McCoy et al. | Development of reservoir vaginal rings containing dapivirine or hormonal contraceptive steroids | |
Chongmin et al. | Guar gum/ethylcellulose coated pellets for colon-specific drug delivery | |
AU2012272935B2 (en) | Fast dissolving azaperone granulate formulation | |
Jyothi et al. | Venlafaxine Hydrochloride Granules Using Natural Polymers as Multiparticulate Drug Delivery System | |
김신웅 et al. | Preparation of UV-curable Chitosan Derivative Particles for Improving Drug Delivery Efficiency | |
CN103127514B (zh) | 一种可体内注射的药物缓释栓剂 | |
CN107496360A (zh) | 一种阿莫西林可生物降解微球长效缓释制剂及其制备方法 |